Ampio pharmaceuticals receives investigational review board approval for its phase i long covid-19 trial (ap-018)

Englewood, colo., may 10, 2021 /prnewswire/ -- ampio pharmaceuticals (nyse american: ampe), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, today announced that it has received investigational review board (irb) approval to commence enrollment in its ap-018 phase i study using inhaled ampion™ with patients exhibiting prolonged respiratory covid-19 symptoms, known as long (or long-haul) covid, or post-acute sequelae of sars-cov-2.
AMPE Ratings Summary
AMPE Quant Ranking